Advertisement
ELAN vs ZTS
Which Stock Would AI Choose? Elanco Animal Health (ELAN) vs. Zoetis (ZTS) Stock Comparison
Key Takeaways
- ELAN has delivered a 133% gain over the past 52 weeks, significantly outperforming ZTS's 28% decline in the same period.
- ZTS maintains a larger market capitalization of approximately $48 billion compared to ELAN's $11.2 billion, reflecting its established position in the animal health sector.
- Recent product approvals for ELAN, including treatments for screwworm infestations, have boosted sentiment, while ZTS focuses on diagnostic expansions ahead of its upcoming earnings.
- ELAN exhibits higher volatility with a beta of 1.88 versus ZTS's more stable 0.86, appealing to different risk appetites.
- Forward P/E ratios suggest ELAN at 20.83 and ZTS at 16.26, with ZTS showing a more attractive PEG ratio of 1.85 (price/earnings to growth).
Introduction
Elanco Animal Health (ELAN) and Zoetis (ZTS) are prominent players in the animal health industry, providing pharmaceuticals, vaccines, and diagnostics for companion animals and livestock. This stock comparison is particularly relevant for investors seeking exposure to the growing pet care and food animal sectors, amid rising demand driven by pet humanization trends and global protein needs. Traders may find value in analyzing their relative performance, as both navigate regulatory approvals, earnings cycles, and market rotations in healthcare. Understanding their contrasts in momentum, valuation, and risk can inform portfolio positioning in the current market environment.
ELAN Overview and Recent Performance
Elanco Animal Health (ELAN) develops and markets products for animal health, spanning farm animals like cattle and swine, as well as pets. In recent market activity, ELAN shares have shown strong upward momentum, trading around $22.50 with a market cap of $11.2 billion. The stock has climbed over 130% in the past year from a 52-week low of $9.42, influenced by robust fourth-quarter results and new emergency use authorizations for products like Negasunt™ Powder and Tanidil™ against New World screwworm in livestock. Analyst sentiment remains positive, with buy ratings and price targets averaging $28.57, though upcoming first-quarter earnings introduce some uncertainty. Higher beta reflects volatility tied to regulatory wins and sector shifts.
ZTS Overview and Recent Performance
Zoetis (ZTS), the world's leading animal health company, offers a broad portfolio of medicines and diagnostics, with strength in companion animal dermatology and livestock vaccines. Recently, ZTS shares have faced pressure, trading near $114 with a $48 billion market cap, down 28% from its 52-week high of $172.23. Despite beating fourth-quarter EPS (earnings per share) estimates at $1.48, recent weeks have seen underperformance amid broader market dynamics. Positive developments include expansions in Vetscan OptiCell capabilities and AI diagnostics focus, with first-quarter earnings due soon and expectations for growth. Lower beta underscores relative stability, though high debt levels warrant monitoring.
Trending AI Robots
Tickeron's Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 350 available models that trade thousands of tickers across diverse strategies, timeframes, and styles. These bots feature impressive stats, including annualized returns from +23% to +163%, win rates between 51% and 88%, and varying trade frequencies tailored to current market conditions like volatility in semiconductors or industrials. For instance, leading bots report high returns on tickers in data centers and space sectors. This selective list highlights bots with proven consistency, helping traders identify suitable automated strategies without manual screening. Explore the page to discover bots matching your risk profile and market outlook.
Head-to-Head Comparison
Both ELAN and ZTS operate in the animal health space, but ZTS emphasizes companion animals with higher-margin diagnostics, while ELAN balances livestock and pets amid restructuring. Growth drivers differ: ELAN's recent approvals provide catalysts, contrasting ZTS's innovation pipeline like AI tools. Momentum favors ELAN with superior relative performance, but ZTS offers stability via lower beta and stronger EPS track record. Risk factors include ELAN's elevated volatility and both firms' high debt-to-equity ratios—67.9% for ELAN versus 279% for ZTS. Market sentiment tilts toward ELAN's rebound, though ZTS appears undervalued per some analyses.
Tickeron AI Verdict
Tickeron's AI models would likely favor ELAN in the current environment due to its consistent upward trend, recent regulatory catalysts, and superior relative momentum over the past year. While ZTS provides greater scale and stability, its recent share price weakness reduces short-term appeal. This probabilistic edge for ELAN stems from observable trend strength and positioning, though shifting earnings outcomes could alter dynamics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAN is a Buy and ZTS is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ELAN’s FA Score shows that 1 FA rating(s) are green whileZTS’s FA Score has 2 green FA rating(s).
- ELAN’s FA Score: 1 green, 4 red.
- ZTS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ELAN’s TA Score shows that 5 TA indicator(s) are bullish while ZTS’s TA Score has 5 bullish TA indicator(s).
- ELAN’s TA Score: 5 bullish, 2 bearish.
- ZTS’s TA Score: 5 bullish, 2 bearish.
Price Growth
ELAN (@Pharmaceuticals: Generic) experienced а +2.59% price change this week, while ZTS (@Pharmaceuticals: Generic) price change was -3.88% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.45%. For the same industry, the average monthly price growth was +3.29%, and the average quarterly price growth was +13.29%.
Reported Earning Dates
ELAN is expected to report earnings on Aug 10, 2026.
ZTS is expected to report earnings on Aug 06, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (+2.45% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| ELAN | ZTS | ELAN / ZTS | |
| Capitalization | 12.5B | 31.4B | 40% |
| EBITDA | 731M | 4.06B | 18% |
| Gain YTD | 10.473 | -40.036 | -26% |
| P/E Ratio | 374.14 | 12.44 | 3,007% |
| Revenue | 4.89B | 9.53B | 51% |
| Total Cash | 428M | 1.94B | 22% |
| Total Debt | 3.99B | 9.24B | 43% |
ELAN | ZTS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 25 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 93 | 17 | |
PRICE GROWTH RATING 1..100 | 44 | 65 | |
P/E GROWTH RATING 1..100 | 1 | 94 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ZTS's Valuation (6) in the Pharmaceuticals Generic industry is significantly better than the same rating for ELAN (92) in the Agricultural Commodities Or Milling industry. This means that ZTS’s stock grew significantly faster than ELAN’s over the last 12 months.
ZTS's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as ELAN (100) in the Agricultural Commodities Or Milling industry. This means that ZTS’s stock grew similarly to ELAN’s over the last 12 months.
ZTS's SMR Rating (17) in the Pharmaceuticals Generic industry is significantly better than the same rating for ELAN (93) in the Agricultural Commodities Or Milling industry. This means that ZTS’s stock grew significantly faster than ELAN’s over the last 12 months.
ELAN's Price Growth Rating (44) in the Agricultural Commodities Or Milling industry is in the same range as ZTS (65) in the Pharmaceuticals Generic industry. This means that ELAN’s stock grew similarly to ZTS’s over the last 12 months.
ELAN's P/E Growth Rating (1) in the Agricultural Commodities Or Milling industry is significantly better than the same rating for ZTS (94) in the Pharmaceuticals Generic industry. This means that ELAN’s stock grew significantly faster than ZTS’s over the last 12 months.
| ELAN | ZTS | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 65% |
| Stochastic ODDS (%) | 3 days ago 72% | 3 days ago 54% |
| Momentum ODDS (%) | 3 days ago 61% | 3 days ago 74% |
| MACD ODDS (%) | 3 days ago 63% | N/A |
| TrendWeek ODDS (%) | 3 days ago 70% | 3 days ago 63% |
| TrendMonth ODDS (%) | 3 days ago 72% | 3 days ago 64% |
| Advances ODDS (%) | 6 days ago 66% | 3 days ago 49% |
| Declines ODDS (%) | 4 days ago 75% | 5 days ago 60% |
| BollingerBands ODDS (%) | N/A | 3 days ago 57% |
| Aroon ODDS (%) | N/A | 3 days ago 43% |
Advertisement
ELAN and
Correlation & Price change
A.I.dvisor indicates that over the last year, ELAN has been loosely correlated with PAHC. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ELAN jumps, then PAHC could also see price increases.
| Ticker / NAME | Correlation To ELAN | 1D Price Change % | ||
|---|---|---|---|---|
| ELAN | 100% | +3.78% | ||
| PAHC - ELAN | 46% Loosely correlated | N/A | ||
| ZTS - ELAN | 44% Loosely correlated | +3.24% | ||
| VTRS - ELAN | 39% Loosely correlated | N/A | ||
| SNDL - ELAN | 39% Loosely correlated | N/A | ||
| AMRX - ELAN | 34% Loosely correlated | N/A | ||
More | ||||